{
    "nctId": "NCT05935384",
    "briefTitle": "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation",
    "officialTitle": "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation",
    "overallStatus": "RECRUITING",
    "conditions": "Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 440,
    "primaryOutcomeMeasure": "Sensitivity of ctDNA to Detect Disease Progression",
    "eligibilityCriteria": "* Will be treated with a first- or second-line systemic and/or oral standard of care regimen at the enrolling site\n* Patient is either treatment naive and has not yet commenced first line SOC therapy OR patient has completed a prior line of SOC therapy and will commence subsequent line of SOC therapy\n* Provide written informed consent to participate in the study\n* Diagnosed with an unresectable advanced solid malignancy and have a histologically confirmed cancer that qualifies for inclusion, defined as:\n\n  * Non-small cell lung cancer (stage III-IV)\n  * Colorectal adenocarcinoma (stage III-IV)\n  * Breast Cancer (stage III-IV)\n\nExclusion Criteria:\n\n* History of a prior solid or hematological malignancy within 5 years of enrollment\n* Life expectancy \\< 12 weeks\n* Unable to collect baseline blood sample prior to starting SOC regimen\n* Is participating in an interventional clinical trial or another observational study that is evaluating the performance of another genomic test for detecting/predicting clinical response/progression",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}